You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

Investigational Drug Information for LOXO-305


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug LOXO-305?

LOXO-305 is an investigational drug.

There have been 26 clinical trials for LOXO-305. The most recent clinical trial was a Phase 1 trial, which was initiated on March 9th 2021.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Loxo Oncology, Inc., Eli Lilly and Company, and M.D. Anderson Cancer Center.

There are four US patents protecting this investigational drug and sixty-two international patents.

Recent Clinical Trials for LOXO-305
TitleSponsorPhase
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesMedical College of WisconsinPhase 1
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple SclerosisEli Lilly and CompanyPhase 2
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple SclerosisLoxo Oncology, Inc.Phase 2

See all LOXO-305 clinical trials

Clinical Trial Summary for LOXO-305

Top disease conditions for LOXO-305
Top clinical trial sponsors for LOXO-305

See all LOXO-305 clinical trials

US Patents for LOXO-305

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LOXO-305 ⤷  Sign Up Compounds useful as kinase inhibitors Loxo Oncology, Inc. (Stamford, CT) ⤷  Sign Up
LOXO-305 ⤷  Sign Up Compounds useful as kinase inhibitors Loxo Oncology Inc. ⤷  Sign Up
LOXO-305 ⤷  Sign Up Compounds useful as kinase inhibitors Loxo Oncology, Inc. (Stamford, CT) ⤷  Sign Up
LOXO-305 ⤷  Sign Up ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LOXO-305

Drugname Country Document Number Estimated Expiration Related US Patent
LOXO-305 Australia AU2016373530 2035-12-16 ⤷  Sign Up
LOXO-305 Australia AU2021201811 2035-12-16 ⤷  Sign Up
LOXO-305 Australia AU2021225161 2035-12-16 ⤷  Sign Up
LOXO-305 Australia AU2021225162 2035-12-16 ⤷  Sign Up
LOXO-305 Brazil BR112018012341 2035-12-16 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.